Camp4 Board Appoints Michael Maclean for Promising Growth
CAMP4 Therapeutics has appointed Michael MacLean to its board of directors as the company readies CMP-002, an antisense oligonucleotide...
Serina Therapeutics: 2025 Financials & Business Highlights
Serina Therapeutics has opened a Phase 1b clinical trial of SER-252, a subcutaneous apomorphine candidate built on the company’s...
Exicure, Inc. Reports Full Year 2025 Financial Results
Exicure reported 2025 results that underscore a high-stakes pivot and an urgent need for capital. Cash fell to $3.7...
Announcing Kura Oncology’s New Approved Inducement Grants
Kura Oncology has granted inducement stock options to six new employees, covering 153,750 shares at an exercise price of...
Syndax Announces Important New Grants Per Nasdaq Listing Rule
Syndax Pharmaceuticals has granted inducement stock options for up to 228,500 shares to eight new employees under its 2023...
Serina Therapeutics 2025 Financial Results & Highlights
Serina Therapeutics has secured FDA IND clearance for SER-252 and initiated dosing in a randomized Phase 1b study in...
Journey Medical Corp. Reports Full-Year 2025 Financials
Journey Medical reported full-year 2025 revenue of $61.9 million, up 10% year over year, driven by the first commercial...
Humacyte Announces Q4 and Year End 2025 Financial Results
Humacyte reported fourth-quarter and full-year 2025 results alongside a string of commercialization and regulatory moves for its bioengineered vessel...
Genfit: 2025 Annual Financial Results & Activity Update
Genfit reported full-year 2025 results and a 2026 outlook that pivots the company from a single‑asset story to a...
Adagene Reports Full Year 2025 Financial Results & Update
Adagene reported 2025 results and advanced its lead program, muzastotug (ADG126), a masked anti-CTLA-4 antibody now showing dose-dependent activity...